Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study

[Background] Patients with severe allergic and eosinophilic asthma could qualify for different biologic therapies.

Bibliographic Details
Authors: Pérez de Llano, Luis A., Cosio, Borja G., Domingo, Christian, Urrutia, Isabel, Bobolea, Irina, Valero, Antonio, Entrenas Costa, Luis M., Quirce, Santiago, Barranco, Pilar, Malanda, Nuria Marina, Prieto Andrés, Luis, Álvarez Gutiérrez, Francisco Javier
Format: article
Status:Published version
Publication Date:2019
Country:España
Institution:Consejo Superior de Investigaciones Científicas (CSIC)
Repository:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/213892
Online Access:http://hdl.handle.net/10261/213892
Access Level:Open access
Keyword:Asthma
Asthma management
Severe asthma
Omalizumab
Reslizumab
Description
Summary:[Background] Patients with severe allergic and eosinophilic asthma could qualify for different biologic therapies.

Similar Items